David Urech, Numab Therapeutics CEO
May 28, 2024 10:22 AM EDT
Deals
Pharma

J&J makes an­oth­er I&I ac­qui­si­tion with $1.25B deal for Num­ab's Yel­low Jer­sey

Kyle LaHucik

Senior Reporter

John­son & John­son is spend­ing $1.25 bil­lion in cash to buy Yel­low Jer­sey Ther­a­peu­tics, mark­ing its sec­ond ac­qui­si­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times